Bridgefront Capital LLC Sells 6,779 Shares of AbbVie Inc. $ABBV

Bridgefront Capital LLC cut its holdings in AbbVie Inc. (NYSE:ABBV) by 53.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,963 shares of the company’s stock after selling 6,779 shares during the quarter. Bridgefront Capital LLC’s holdings in AbbVie were worth $1,381,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its holdings in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its position in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. increased its holdings in shares of AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the period. Impax Asset Management Group plc bought a new position in shares of AbbVie in the 2nd quarter worth $990,000. Finally, Foundations Investment Advisors LLC raised its position in shares of AbbVie by 10.4% in the 2nd quarter. Foundations Investment Advisors LLC now owns 24,913 shares of the company’s stock worth $4,624,000 after acquiring an additional 2,346 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by corporate insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase‑1 data for ABBV‑295 reported as encouraging — supports pipeline optionality beyond core brands and is constructive for long‑term revenue upside. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology — reinforces management’s growth strategy in a key therapeutic area. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: RBC Capital started coverage with an Outperform and $260 price target — a bullish institutional view that supports upside versus current levels. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: Consensus analyst stance remains supportive (“Moderate Buy”), which provides a baseline of buy‑side conviction. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Allergan Aesthetics‑affiliated providers earned top rankings in NY (beneficial for Allergan Aesthetics’ commercial reputation, but limited immediate impact on ABBV stock). New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Features and listicles (e.g., halal/debt‑free stock roundup, retirement income pieces) mention AbbVie but are peripheral to near‑term price movement. Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy?
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies expand the market opportunity for psychiatric drugs broadly; indirect for AbbVie unless tied to specific assets. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Shareholder governance concern: reports that the AbbVie CEO’s pay package has spiked above $30M can weigh on sentiment and prompt selling by governance‑focused funds. J&J, AbbVie CEOs See Pay Spike to More Than $30M
• Negative Sentiment: Analyst debate about immunology competition and valuation creates two‑sided risk—some analysts lift targets on growth, others flag competition that could cap upside, encouraging short‑term profit‑taking. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks

AbbVie Stock Down 2.5%

Shares of AbbVie stock opened at $219.73 on Friday. The firm has a market capitalization of $388.51 billion, a P/E ratio of 93.10, a PEG ratio of 0.76 and a beta of 0.34. The company has a 50 day moving average price of $224.33 and a 200 day moving average price of $224.67. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Citigroup lowered their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, Royal Bank Of Canada started coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.